Controlled-release biocompatible ocular drug delivery implant devices and methods
VG Wong, MWL Hu, DE Berger Jr - US Patent 6,331,313, 2001 - Google Patents
3,921,632 11/1975 Bardani. 4,008,864 2/1977 Torphammar et al.. 4,063,064 12/1977
Saunders et al.. patible and can be implanted into the eye. The devices have a core …
Saunders et al.. patible and can be implanted into the eye. The devices have a core …
Protein matrix materials, devices and methods of making and using thereof
DB Masters - US Patent 7,662,409, 2010 - Google Patents
The present invention relates to protein matrix materials and devices and the methods of
making and using protein matrix materials and devices. More specifically the present …
making and using protein matrix materials and devices. More specifically the present …
Patent literature review of ophthalmic inserts
F Gurtler, R Gurny - Drug development and industrial pharmacy, 1995 - Taylor & Francis
In the area of topical ocular administration, important efforts concern the design and the
conception of new ophthalmic drug delivery systems able to prolong the residence time. The …
conception of new ophthalmic drug delivery systems able to prolong the residence time. The …
Methods and apparatus for delivery of ocular implants
DA Weber, I Kane, M Rehal, RL Lathrop III… - US Patent …, 2006 - Google Patents
5,378.475 A 1/1995 Smith et al................. 424/473 EP O544948 B1 9, 1995 5,443,505 A
8/1995 Wong et al.... 623/4 WO WO 99.33512 7, 1999 5,451,213 A 9, 1995 Teicher et al. WO …
8/1995 Wong et al.... 623/4 WO WO 99.33512 7, 1999 5,451,213 A 9, 1995 Teicher et al. WO …
Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
H Guo, P Ashton - US Patent 6,375,972, 2002 - Google Patents
A method and device for treating a mammalian organism to obtain a desired local or
systemic physiological or pharmacological effect is provided. The method includes …
systemic physiological or pharmacological effect is provided. The method includes …
Hypotensive lipid-containing biodegradable intraocular implants and related methods
PM Hughes - US Patent 7,799,336, 2010 - Google Patents
4. 85 3. 224 A 8, 1989 Man O for an extended period of time. The prostamide component 4s
63.457 A 9, 1989 g may be associated with a biodegradable polymer matrix. Such 4s65s46 …
63.457 A 9, 1989 g may be associated with a biodegradable polymer matrix. Such 4s65s46 …
Implantable drug delivery device and use thereof
AP Adamis, JW Miller, ES Gragoudas… - US Patent …, 2009 - Google Patents
60 Provisional a lication No. 60/288,373,? led on Ma.......() 3, 2001, provigional application
No. 60/291,340,? led The? mvempn provldes a mlmamilzeq'Implantable dmg on May 16 …
No. 60/291,340,? led The? mvempn provldes a mlmamilzeq'Implantable dmg on May 16 …
Controlled release liquid delivery compositions with low initial drug burst
BL Chandrashekar, M Zhou, EM Jarr… - US Patent 6,143,314, 2000 - Google Patents
BACKGROUND OF THE INVENTION A variety of approaches have been developed to
permit controlled, sustained release of a biologically active agent into a subject. Examples of …
permit controlled, sustained release of a biologically active agent into a subject. Examples of …
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
VG Wong - US Patent 6,699,493, 2004 - Google Patents
Methods for reducing or preventing transplant rejection in the eye of an individual are
described, comprising: a) performing an ocular transplant procedure; and b) implant ing in …
described, comprising: a) performing an ocular transplant procedure; and b) implant ing in …
Extended therapeutic effect ocular implant treatments
S Whitcup, D Weber - US Patent App. 10/837,357, 2005 - Google Patents
BACKGROUND 0001. This invention relates to methods for extended treatment of an ocular
condition. In particular, the present invention releases to methods for extended treatment of …
condition. In particular, the present invention releases to methods for extended treatment of …